Medication Development for the Treatment of Cocaine Dependence: Issues in Clinical Efficacy Trials

Editors:

Betty Tai, Ph.D.

Nora Chiang, Ph.D.

Peter Bridge, M.D.

NIDA Research Monograph 175
1997

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute on Drug Abuse
Office of Science Policy and Communications
5600 Fishers Lane
Rockville, MD 20857
ACKNOWLEDGMENT

This monograph is based on the papers from a technical review “Medication Development for the Treatment of Cocaine Dependence: Issues in Clinical Efficacy Trials” held on October 20-21, 1994. The review meeting was sponsored by the National Institute on Drug Abuse.

COPYRIGHT STATUS

The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated.

Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services.

The U.S. Government does not endorse or favor any specific commercial product or company. Trade, proprietary, or company names appearing in this publication are used only because they are considered essential in the context of the studies reported herein.

National Institute on Drug Abuse
NIH Publication No. 97-4125
Printed 1997

NIDA Research Monographs are indexed in the Index Medicus. They are selectively included in the coverage of American Statistics Index, BioSciences Information Service, Chemical Abstracts, Current Contents, Psychological Abstracts, and Psychopharmacology Abstracts.
<table>
<thead>
<tr>
<th>Table of Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preface ...........................................................................................................1</td>
</tr>
<tr>
<td>Betty Tai, Charles V. Grudzinskas, Nora Chiang, and Peter Bridge</td>
</tr>
<tr>
<td>Goals and Rationale for Pharmacotherapeutic Approach in Treating Cocaine Dependence: Insights From Basic and Clinical Research ...........................................................................5</td>
</tr>
<tr>
<td>Mary Jeanne Kreek</td>
</tr>
<tr>
<td>Overview of Potential Treatment Medications for Cocaine Dependence ..........................................................36</td>
</tr>
<tr>
<td>Elinore F. McCance</td>
</tr>
<tr>
<td>Methodologic Recommendations for Cocaine Abuse Clinical Trials: A Clinician-Researcher’s Perspective .................................................................73</td>
</tr>
<tr>
<td>Edward V. Nunes</td>
</tr>
<tr>
<td>Management of Clinical Trials With New Medications for Cocaine Dependence and Abuse ........................................................................96</td>
</tr>
<tr>
<td>Ari Kiev</td>
</tr>
<tr>
<td>Outcome Measurement Considerations: Pharmacological Treatments for Substance Abuse ...............................................................................118</td>
</tr>
<tr>
<td>Karla Moras</td>
</tr>
<tr>
<td>Variability in Treatment-Seeking Cocaine Abusers: Implications for Clinical Pharmacotherapy Trials ........................................................................137</td>
</tr>
<tr>
<td>Kathleen M. Carroll, Charla Nich, and Bruce J. Rounsaville</td>
</tr>
<tr>
<td>Baseline Assessment, Study Entry, and Stabilization: Double-Blind Clinical Trials in Drug Dependence ........................................................................158</td>
</tr>
<tr>
<td>John Grabowski, Gila Arnoni, Ronith Elk, Howard Rhoades, and Joy Schmitz</td>
</tr>
<tr>
<td>The Addiction Severity Index in Clinical Efficacy Trials of Medications for Cocaine Dependence ........................................................................182</td>
</tr>
</tbody>
</table>
Cognitive-Neuromotor Assessment of Substance Abuse:
Focus on Issues Related to Cocaine Abuse Treatment.........................192
E.H. Ellinwood, Jr. and T.H. Lee

Treatment Effectiveness Score as an Outcome Measure in
Clinical Trials................................................................................208
Walter Ling, Steven Shoptaw, Donald Wesson, Richard A.
Rawson, Margaret Compton, and C. James Klett

Pharmacokinetics of Cocaine: Considerations When Assessing
Cocaine Use by Urinalysis.............................................................221
Reese T. Jones

Quantitative Urine Levels of Cocaine and Other Substances
of Abuse........................................................................................235
Jeffery N. Wilkins

Use of Quantitative Urinalysis in Monitoring Cocaine Use...........253
Kenzie L. Preston, Kenneth Silverman, Charles R. Schuster,
and Edward J. Cone

Is Quantitative Urinalysis More Sensitive?.................................265
Shou-Hua Li, Nora Chiang, Betty Tai, Charles K.
Marschke, and Richard L. Hawks

Comparison of Immunoassays for Semiquantitative Measurement
of Benzoylcegonine in Urine..........................................................287
Rodger L. Foltz, Christine Botelho, Scott A. Reuschel,
David J. Kuntz, David E. Moody, and Gloria M. Bristow

Appendix I: Workshop Summary Outcome Measures and
Success Criteria..............................................................................303
Betty Tai

Appendix II: Workshop Summary Clinical Decision Tree for
Cocaine Addiction Pharmacotherapy.............................................312
Betty Tai, Charles V. Grudzinskas, Peter Bridge, and
Nora Chiang